VC: the smart money's in Australia, not the US
14 April, 2003 by Jeremy TorrA Sydney biotech conference has heard that the gold rush for venture capital in the US is becoming so constrained it makes sense to look at home.
Get familiar with new ASX rules, biotechs told
11 April, 2003 by Melissa TrudingerBiotechnology companies should make themselves aware of the new guidelines for corporate governance released by the ASX recently, says Chris Sotiropoulos, VP for commercialisation at Melbourne-based technology business development and commercialisation company Biocomm.
Seller beware: what do buyers of scientific equipment want?
10 April, 2003 by Melissa TrudingerKeeping up with the Joneses has become critical in research, where the race to achieve an important result not only guarantees a high-profile paper, but in the increasingly commercial world can provide an edge over a competing interest.
Circadian soars on buyback plan
10 April, 2003 by Melissa TrudingerIn a move that caused a 35 cent jump in the company's stock price, Melbourne firm Circadian announced yesterday that it would buy back up to 10 per cent of the company's outstanding shares.
CSIRO looking for growth in funding
04 April, 2003 by Simon GroseCSIRO chief executive Dr Geoff Garrett will have more riding on the May 13 Federal budget than most Australians. Halfway through his five-year appointment, he will be wanting to show his staff that they can look forward to real growth in public funding in the years ahead. If not, their disgruntlement over his challenging leadership may render the second half of his tenure more challenged than the first.
IBM, VPAC standardising bio-IT platform with $1m server
03 April, 2003 by David BraueThe amount of computing power available to Australian bioinformatics researchers continues to climb, with the Victorian Partnership for Advanced Computing (VPAC) this week switching on a massive $1 million clustered server from IBM that will more than double the organisation's computing power.
Govts urged to support homegrown tech
02 April, 2003 by Iain ScottStart-ups are hard work and technology-based start-ups even harder, the CEO of one of Australia's best-known such ventures told last week's KCA commercialisation conference.
Research strengths key to good tech transfer: Penn head
01 April, 2003 by Iain ScottEminent scientists should remain in the lab producing research results, rather than join a start-up company based on their work, according to the head of one of the most successful technology transfer offices in the US.
BigShop loses bid for Biota board
28 March, 2003 by Melissa TrudingerA bid by Perth entrepreneur Farooq Khan to win a seat on the board of Biota Holdings was defeated by other shareholders at a heated meeting in Melbourne this afternoon.
Tapping biotech's human resources
27 March, 2003 by Pete YoungAlthough Australia has some great researchers coming out of its universities, attracting and keeping scientists and biostatisticians local can be a problem, Pete Young finds.
The value of good researchers
26 March, 2003 by Melissa TrudingerNobel Laureate Prof Peter Doherty is lending his name to a new prize to be awarded at Australia's first Commercialisation Forum and Fair of Ideas, which started in Sydney today and runs to March 28.
Biotech by degrees
25 March, 2003 by Melissa TrudingerUndergraduate level biotechnology degree programs are becoming increasingly popular in Australia, offering students the opportunity to combine the essential basic science requirements with exposure to business and other aspects of the industry.
Bid to oust VRI Biomedical board
21 March, 2003 by Iain ScottOne of Perth-based probiotics company VRI Biomedical's largest shareholders has launched a bid to remove most of the company's board and move key management to Sydney.
Hearts and minds the stakes as Biota-BigShop clash looms
20 March, 2003 by Pete YoungA battle for the hearts and minds of Biota Holdings shareholders is intensifying on the eve of a confrontation between the board of the embattled biotech and its largest stakeholder.
Aussie biotechs should jump on soft US market: Nasdaq VP
18 March, 2003 by Melissa TrudingerThe soft IPO market in the US could be advantageous to Australian biotech companies seeking to raise their profile in the US, Nasdaq Asia-Pacific VP Patrick Sutch told an audience of biotech CEOs in Melbourne today.
